-
1.发明申请Method and Compositions for Stimulation of an Immune Response to gp100 using a Xenogeneic gp100 Antigen 审中-公开使用异种gp100抗原刺激对gp100的免疫应答的方法和组合物公开(公告)号：US20100068216A1
公开(公告)日：2010-03-18
申请号：US12622087
申请日：2009-11-19
IPC分类号： A61K39/00 , A61K31/7088 , A61P35/00
CPC分类号： A61K39/00 , A61K39/0011 , A61K2039/53 , A61K2039/55522 , C07K14/4748
摘要： Tolerance of the immune system for endogenous gp100 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed gp100 antigen. For example, mouse gp100, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against gp100 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing gp100, such as melanoma.
摘要翻译： 可以克服免疫系统对内源性gp100的耐受性，并通过施用异种或异种表达的gp100抗原刺激免疫应答。 例如，可以使用小鼠gp100或其抗原性有效部分来刺激人受试者中对应的分化抗原的免疫应答。 根据本发明的异种抗原的施用导致对治疗个体中由癌症表达的gp100的有效免疫，从而提供治疗表达gp100的癌症（例如黑素瘤）的治疗方法。
-
2.发明申请Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen 审中-公开使用异种TRP2抗原刺激对TRP2的免疫应答的方法和组合物公开(公告)号：US20100068263A1
公开(公告)日：2010-03-18
申请号：US12622103
申请日：2009-11-19
IPC分类号： A61K9/127 , A61K39/00 , A61K31/7052 , A61P37/04
CPC分类号： A61K39/00 , A61K39/0011 , A61K2039/53 , C07K14/705
摘要： Tolerance of the immune system for endogenous TRP2 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed TRP2 antigen. For example, mouse TRP2, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against TRP2 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing TRP2, such as melanoma.
摘要翻译： 可以克服免疫系统对内源性TRP2的耐受性，通过施用异种或异种表达的TRP2抗原刺激免疫应答。 例如，小鼠TRP2或其抗原性有效部分可用于刺激人受试者中相应的分化抗原的免疫应答。 根据本发明的异种抗原的施用导致对治疗个体中由癌症表达的TRP2的有效免疫，从而提供治疗表达TRP2的癌症（例如黑素瘤）的治疗方法。
-
3.发明申请Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen 审中-公开使用异种PSMA抗原刺激对PSMA的免疫反应的方法和组合物公开(公告)号：US20100068262A1
公开(公告)日：2010-03-18
申请号：US12622096
申请日：2009-11-19
IPC分类号： A61K9/127 , A61K39/00 , A61K31/7052 , A61P37/04
CPC分类号： A61K39/00 , A61K39/0011 , A61K2039/53 , A61K2039/545 , C07K14/705
摘要： Tolerance of the immune system for endogenous PSMA can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed PSMA antigen. For example, mouse PSMA, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against PSMA expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing PSMA, such as prostate cancer.
摘要翻译： 可以克服免疫系统对内源性PSMA的耐受性，并通过施用异种或异种表达的PSMA抗原刺激免疫应答。 例如，小鼠PSMA或其抗原性有效部分可用于刺激人受试者中相应的分化抗原的免疫应答。 根据本发明的异种抗原的施用导致对治疗个体中由癌症表达的PSMA的有效免疫，从而提供治疗表达PSMA的癌症（例如前列腺癌）的治疗方法。
-
4.发明授权Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen 有权用于刺激由改变的分化抗原刺激的分化抗原的免疫应答的方法和组合物公开(公告)号：US06328969B1
公开(公告)日：2001-12-11
申请号：US09308697
申请日：1999-05-21
IPC分类号： A61K3908
CPC分类号： A61K39/0011 , A61K39/00 , C07K14/705
摘要： Tolerance of the immune system for self differentiation antigens can be overcome and an immune response stimulated by administration of a therapeutic differentiation antigen. The therapeutic differentiation antigen is altered with respect to the target differentiation antigen in the individual being treated (i.e., the differentiation antigen to which an immune response is desired) in one of three ways. First, the therapeutic differentiation antigen may be syngeneic with the target differentiation antigen, provided that therapeutic differentiation antigen is expressed in cells of a species different from the individual being treated. For example, a human differentiation antigen expressed in insect or other non-human host cells can be used to stimulate an immune response to the differentiation antigen in a human subject. Second, the therapeutic differentiation antigen may be a mutant form of a syngeneic differentiation antigen, for example a glycosylation mutant. Third, the therapeutic differentiation antigen may be a differentiation antigen (wild-type or mutant) of the same type from a species different from the individual being treated. For example, a mouse differentiation antigen can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of altered antigens in accordance with the invention results in an effective immunity against the original antigen expressed by the cancer in the treated individual.
摘要翻译： 可以克服免疫系统对自分化抗原的耐受性，并通过施用治疗性分化抗原刺激免疫应答。 治疗分化抗原相对于待治疗的个体中的靶分化抗原（即，需要免疫应答的分化抗原）以三种方式之一改变。 首先，治疗分化抗原可以与靶分化抗原同源，只要治疗分化抗原在与待治疗的个体不同的物种的细胞中表达即可。 例如，在昆虫或其他非人宿主细胞中表达的人分化抗原可用于刺激人受试者中分化抗原的免疫应答。 其次，治疗性分化抗原可以是突变形式的同基因分化抗原，例如糖基化突变体。 第三，治疗性分化抗原可以是与不同于被治疗个体的物种相同类型的分化抗原（野生型或突变型）。 例如，小鼠分化抗原可用于刺激人受试者中相应的分化抗原的免疫应答。 根据本发明的改变的抗原的施用导致对治疗个体中由癌症表达的原始抗原的有效免疫。
-
公开(公告)号：US06168946A
公开(公告)日：2001-01-02
申请号：US08409794
申请日：1995-03-24
IPC分类号： C12N1512
CPC分类号： C12Y110/03001 , A61K38/00 , A61K39/00 , C07K14/47 , C12N9/0059 , C12N9/0071 , C12Y114/16002 , C12Y114/18001
摘要： The present invention provides an isolated nucleic acid molecule whose sequence encodes the amino acid sequence for gp75 or a fragment thereof. The present invention further provides an isolated cDNA molecule of the gp75 nucleic acid molecule or a fragment thereof and the amino acid sequence derived therefrom. This invention also provides vaccines for stimulating or enhancing in a subject to whom the vaccine is administered production of antibodies directed against gp75. This invention further provides methods using the vaccines of this invention for stimulating or enhancing production of antibodies against gp75 as well as for treating, preventing or delaying the recurrence of cancer.
摘要翻译： 本发明提供了分离的核酸分子，其序列编码gp75的氨基酸序列或其片段。 本发明还提供了gp75核酸分子或其片段的分离的cDNA分子和由其衍生的氨基酸序列。 本发明还提供用于在施用疫苗的受试者中刺激或增强针对gp75的抗体产生的疫苗。 本发明还提供了使用本发明的疫苗刺激或增强针对gp75的抗体的产生以及用于治疗，预防或延迟癌症复发的方法。
-
公开(公告)号：US20050037462A1
公开(公告)日：2005-02-17
申请号：US10877489
申请日：2004-06-25
IPC分类号： C12N15/11 , A61K31/65 , A61K35/36 , A61K38/00 , A61K39/00 , A61K48/00 , A61P35/00 , C07K14/47 , C12N9/02 , C12N15/09 , C12N15/12 , C12N15/53 , C12N15/63 , A61K38/27 , C07H21/04 , C07K7/08
CPC分类号： C12Y110/03001 , A61K38/00 , A61K39/00 , C07K14/47 , C12N9/0059 , C12N9/0071 , C12Y114/16002 , C12Y114/18001
摘要： The present invention provides an isolated nucleic acid molecule whose sequence encodes the amino acid sequence for gp75 or a fragment thereof. The present invention further provides an isolated cDNA molecule of the gp75 nucleic acid molecule or a fragment thereof and the amino acid sequence derived therefrom. This invention also provides vaccines for stimulating or enhancing in a subject to whom the vaccine is administered production of antibodies directed against gp75. This invention further provides methods using the vaccines of this invention for stimulating or enhancing production of antibodies against gp75 as well as for treating, preventing or delaying the recurrence of cancer.
摘要翻译： 本发明提供了分离的核酸分子，其序列编码gp75的氨基酸序列或其片段。 本发明还提供了gp75核酸分子或其片段的分离的cDNA分子和由其衍生的氨基酸序列。 本发明还提供用于在施用疫苗的受试者中刺激或增强针对gp75的抗体产生的疫苗。 本发明还提供了使用本发明的疫苗刺激或增强针对gp75的抗体的产生以及用于治疗，预防或延迟癌症复发的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
